Yüklüyor......
Oncological benefits of portal vein embolization for patients with hepatocellular carcinoma
Portal vein embolization (PVE) for hepatocellular carcinoma (HCC) was first introduced in 1986 and has been continuously developed throughout the years. Basically, PVE has been applied to expand the indication of liver resection for HCC patients of insufficient future liver remnant. Importantly, PVE...
Kaydedildi:
| Yayımlandı: | Ann Gastroenterol Surg |
|---|---|
| Asıl Yazarlar: | , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
John Wiley and Sons Inc.
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8164464/ https://ncbi.nlm.nih.gov/pubmed/34095718 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ags3.12414 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|